Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review)

Ribas A and Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science. 359:1350–1355. 2018. View Article : Google Scholar : PubMed/NCBI

Sharma P, Hu-Lieskovan S, Wargo JA and Ribas A: Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 168:707–723. 2017. View Article : Google Scholar : PubMed/NCBI

Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, Byregowda S, Natarajan SM, Trujillo-Ocampo A, Im JS and Goswami S: Histone lactylation drives CD8⁺ T cell metabolism and function. Nat Immunol. 25:2140–2151. 2024. View Article : Google Scholar : PubMed/NCBI

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI

Deribe YL, Pawson T and Dikic I: Post-translational modifications in signal integration. Nat Struct Mol Biol. 17:666–672. 2010. View Article : Google Scholar : PubMed/NCBI

Dai X, Gao Y and Wei W: Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy. Semin Cancer Biol. 85:246–252. 2022. View Article : Google Scholar

Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, Wei Y, Chou CK, Wang SC, Yan M, et al: Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell. 36:168–178.e4. 2019. View Article : Google Scholar : PubMed/NCBI

Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, Lu H, Fang C, Zhang Y, Liang L, et al: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng. 3:306–317. 2019. View Article : Google Scholar : PubMed/NCBI

Cho KJ and Roche PA: Regulation of MHC class II-peptide complex expression by ubiquitination. Front Immunol. 4:3692013. View Article : Google Scholar : PubMed/NCBI

Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, et al: Metabolic regulation of gene expression by histone lactylation. Nature. 574:575–580. 2019. View Article : Google Scholar : PubMed/NCBI

Britt EC, John SV, Locasale JW and Fan J: Metabolic regulation of epigenetic remodeling in immune cells. Curr Opin Biotechnol. 63:111–117. 2020. View Article : Google Scholar : PubMed/NCBI

Lemma EY, Letian A, Altorki NK and McGraw TE: Regulation of PD-L1 trafficking from synthesis to degradation. Cancer Immunol Res. 11:866–874. 2023. View Article : Google Scholar : PubMed/NCBI

Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, et al: Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 7:126322016. View Article : Google Scholar : PubMed/NCBI

Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, Chen CT, Liao HW, Kuo CW, Khoo KH, et al: STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 9:19082018. View Article : Google Scholar : PubMed/NCBI

Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, et al: Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 30:925–939. 2016. View Article : Google Scholar : PubMed/NCBI

Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, et al: Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 71:606–620.e7. 2018. View Article : Google Scholar : PubMed/NCBI

Li Y, Zhang R and Hei H: Advances in post-translational modifications of proteins and cancer immunotherapy. Front Immunol. 14:12293972023. View Article : Google Scholar : PubMed/NCBI

Zhang H, Yan Q, Jiang S, Hu D, Lu P, Li S, Sandai D, Zhang H, Zhang W and Zhu C: Protein post-translational modifications and tumor immunity: A pan-cancer perspective. Phys Life Rev. 55:142–209. 2025. View Article : Google Scholar : PubMed/NCBI

Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, et al: IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 129:3324–3338. 2019. View Article : Google Scholar : PubMed/NCBI

Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, Wei Y, Xia W, Hou J, Qiu Y and Hung MC: Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 29:83–86. 2019. View Article : Google Scholar

Zhu D, Xu R, Huang X, Tang Z, Tian Y, Zhang J and Zheng X: Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 28:1773–1789. 2021. View Article : Google Scholar

Wilson KR, Liu H, Healey G, Vuong V, Ishido S, Herold MJ, Villadangos JA and Mintern JD: MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway. PLoS One. 13:e02005402018. View Article : Google Scholar : PubMed/NCBI

Liu H, Wilson KR, Firth AM, Macri C, Schriek P, Blum AB, Villar J, Wormald S, Shambrook M, Xu B, et al: Ubiquitin-like protein 3 (UBL3) is required for MARCH ubiquitination of major histocompatibility complex class II and CD86. Nat Commun. 13:19342022. View Article : Google Scholar : PubMed/NCBI

Apriamashvili G, Vredevoogd DW, Krijgsman O, Bleijerveld OB, Ligtenberg MA, de Bruijn B, Boshuizen J, Traets JJH, D'Empaire Altimari D, van Vliet A, et al: Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling. Nat Commun. 13:19232022. View Article : Google Scholar

De Leo A, Ugolini A, Yu X, Scirocchi F, Scocozza D, Peixoto B, Pace A, D'Angelo L, Liu JKC, Etame AB, et al: Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity. 57:1105–1123.e8. 2024. View Article : Google Scholar : PubMed/NCBI

Wang R, Li C, Cheng Z, Li M, Shi J, Zhang Z, Jin S and Ma H: H3K9 lactylation in malignant cells facilitates CD8⁺ T cell dysfunction and poor immunotherapy response. Cell Rep. 43:1149572024. View Article : Google Scholar

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al: Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 165:35–44. 2016. View Article : Google Scholar : PubMed/NCBI

Meng K and Lu H: Clinical application of high-LET radiotherapy combined with immunotherapy in malignant tumors. Precis Radiat Oncol. 8:42–46. 2024. View Article : Google Scholar : PubMed/NCBI

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI

Mukai K, Konno H, Akiba T, Uemura T, Waguri S, Kobayashi T, Barber GN, Arai H and Taguchi T: Activation of STING requires palmitoylation at the Golgi. Nat Commun. 7:119322016. View Article : Google Scholar : PubMed/NCBI

Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, et al: Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 534:55–62. 2016. View Article : Google Scholar : PubMed/NCBI

Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, Petralia F, Li Y, Liang WW, Reva B, et al: Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell. 182:200–225.e35. 2020. View Article : Google Scholar : PubMed/NCBI

Li Y, Porta-Pardo E, Tokheim C, Bailey MH, Yaron TM, Stathias V, Geffen Y, Imbach KJ, Cao S, Anand S, et al: Pan-cancer proteogenomics connects oncogenic drivers to functional states. Cell. 186:3921–3944.e25. 2023. View Article : Google Scholar : PubMed/NCBI

Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, Sugiura A, Cohen AS, Ali A, Do BT, et al: Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 593:282–288. 2021. View Article : Google Scholar : PubMed/NCBI

Ma S, Dahabieh MS, Mann TH, Zhao S, McDonald B, Song WS, Chung HK, Farsakoglu Y, Garcia-Rivera L, Hoffmann FA, et al: Nutrient-driven histone code determines exhausted CD8⁺ T cell fates. Science. 387:eadj30202025. View Article : Google Scholar

Rozalén C, Sangrador I, Avalle S, Blasco-Benito S, Tzortzi P, Sanz-Flores M, Palomeque JÁ, Torren-Duran P, Dalmau M, Brunel H, et al: TIM3⁺ breast cancer cells license immune evasion during micrometastasis outbreak. Cancer Cell. 43:1549–1567.e9. 2025. View Article : Google Scholar

Guo M, Yuan Z, Jin X, Li X, Deng Y, Zhou S, Niu R, Bae J, Park JB, Shi B and Yin J: Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via β-catenin/PD-L1 signaling. Nat Commun. 16:86422025. View Article : Google Scholar

Chu CW, Čaval T, Alisson-Silva F, Tankasala A, Guerrier C, Czerwieniec G, Läubli H and Schwarz F: Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors. Life Sci Alliance. 7:e2023023682024. View Article : Google Scholar : PubMed/NCBI

Benicky J, Sanda M, Brnakova Kennedy Z, Grant OC, Woods RJ, Zwart A and Goldman R: PD-L1 glycosylation and its impact on binding to clinical antibodies. J Proteome Res. 20:485–497. 2021. View Article : Google Scholar

Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, et al: In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 547:413–418. 2017. View Article : Google Scholar : PubMed/NCBI

Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A, Pedersen B, Irvine M, Alavi S, Yang JYH, et al: Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. Nat Commun. 11:18972020. View Article : Google Scholar

Cho KJ, Walseng E, Ishido S and Roche PA: Ubiquitination by March-I prevents MHC class II recycling and promotes MHC class II turnover in antigen-presenting cells. Proc Natl Acad Sci USA. 112:10449–10454. 2015. View Article : Google Scholar : PubMed/NCBI

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, et al: Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 171:934–949.e16. 2017. View Article : Google Scholar : PubMed/NCBI

Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB and Balko JM: Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 7:e14381062018. View Article : Google Scholar : PubMed/NCBI

Liau NPD, Laktyushin A, Lucet IS, Murphy JM, Yao S, Whitlock E, Callaghan K, Nicola NA, Kershaw NJ and Babon JJ: The molecular basis of JAK/STAT inhibition by SOCS1. Nat Commun. 9:15582018. View Article : Google Scholar : PubMed/NCBI

Zhang JG, Metcalf D, Rakar S, Asimakis M, Greenhalgh CJ, Willson TA, Starr R, Nicholson SE, Carter W, Alexander WS, et al: The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc Natl Acad Sci USA. 98:13261–13265. 2001. View Article : Google Scholar : PubMed/NCBI

Alicea Pauneto CDM, Riesenberg BP, Gandy EJ, Kennedy AS, Clutton GT, Hem JW, Hurst KE, Hunt EG, Green JM, Miller BC, et al: Intra-tumoral hypoxia promotes CD8⁺ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity. 58:2489–2504.e8. 2025. View Article : Google Scholar

Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, Carter R, Awad W, Neale G, Thomas PG and Youngblood B: De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 170:142–157.e19. 2017. View Article : Google Scholar : PubMed/NCBI

Petralia F, Ma W, Yaron TM, Caruso FP, Tignor N, Wang JM, Charytonowicz D, Johnson JL, Huntsman EM, Marino GB, et al: Pan-cancer proteogenomics characterization of tumor immunity. Cell. 187:1255–1277.e27. 2024. View Article : Google Scholar : PubMed/NCBI

Li Y, Dou Y, Da Veiga Leprevost F, Geffen Y, Calinawan AP, Aguet F, Akiyama Y, Anand S, Birger C, Cao S, et al: Proteogenomic data and resources for pan-cancer analysis. Cancer Cell. 41:1397–1406. 2023. View Article : Google Scholar : PubMed/NCBI

Kacen A, Javitt A, Kramer MP, Morgenstern D, Tsaban T, Shmueli MD, Teo GC, da Veiga Leprevost F, Barnea E, Yu F, et al: Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. Nat Biotechnol. 41:239–251. 2023. View Article : Google Scholar

Yeh CY, Aguirre K, Laveroni O, Kim S, Wang A, Liang B, Zhang X, Han LM, Valbuena R, Bassik MC, et al: Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer. Nat Immunol. 25:1943–1958. 2024. View Article : Google Scholar : PubMed/NCBI

Xu Y, Wang X, Li Y, Mao Y, Su Y, Mao Y, Yang Y, Gao W, Fu C, Chen W, et al: Multimodal single cell-resolved spatial proteomics reveal pancreatic tumor heterogeneity. Nat Commun. 15:101002024. View Article : Google Scholar : PubMed/NCBI

Mateiou C, Lokhande L, Diep LH, Knulst M, Carlsson E, Ek S, Sundfeldt K and Gerdtsson A: Spatial tumor immune microenvironment phenotypes in ovarian cancer. NPJ Precis Oncol. 8:1482024. View Article : Google Scholar : PubMed/NCBI

Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Salié H, Vollmer L, Kuliesiute U, von Ehr J, Benotmane JK, et al: Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell. 40:639–655.e13. 2022. View Article : Google Scholar : PubMed/NCBI

Yu B, Qi C, Liu Z, Ma N, Tian C, Wang Y, Li C and Li Z: Spatial heterogeneity of PD-L1 expression influence its assessment in esophageal squamous cell carcinoma. Transl Oncol. 59:1024422025. View Article : Google Scholar : PubMed/NCBI

Chung CR, Tang Y, Chiu YP, Li S, Hsieh WK, Yao L, Chiang YC, Pang Y, Chen GT, Chou KC, et al: dbPTM 2025 update: Comprehensive integration of PTMs and proteomic data for advanced insights into cancer research. Nucleic Acids Res. 53(D1): D377–D386. 2025. View Article : Google Scholar :

Yi X, Liao Y, Wen B, Li K, Dou Y, Savage SR and Zhang B: caAtlas: An immunopeptidome atlas of human cancer. iScience. 24:1031072021. View Article : Google Scholar : PubMed/NCBI

Huang X, Gan Z, Cui H, Lan T, Liu Y, Caron E and Shao W: The SysteMHC Atlas v2.0, an updated resource for mass spectrometry-based immunopeptidomics. Nucleic Acids Res. 52(D1): D1062–D1071. 2024. View Article : Google Scholar :

Aung TN, Monkman J, Warrell J, Vathiotis I, Bates KM, Gavrielatou N, Trontzas IP, Tan CW, Fernandez AI, Moutafi M, et al: Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer. Nat Genet. 57:2482–2493. 2025. View Article : Google Scholar : PubMed/NCBI

Califf RM: Biomarker definitions and their applications. Exp Biol Med (Maywood). 243:213–221. 2018. View Article : Google Scholar : PubMed/NCBI

Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, et al: The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res. 24:3366–3376. 2018. View Article : Google Scholar : PubMed/NCBI

Thompson JC, Davis C, Deshpande C, Hwang WT, Jeffries S, Huang A, Mitchell TC, Langer CJ and Albelda SM: Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J Immunother Cancer. 8:e0009742020. View Article : Google Scholar : PubMed/NCBI

Han J, Dong Y, Zhu X, Reuben A, Zhang J, Xu J, Bai H, Duan J, Wan R, Zhao J, et al: Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nat Commun. 15:11992024. View Article : Google Scholar : PubMed/NCBI

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, et al: Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res. 23:5024–5033. 2017. View Article : Google Scholar : PubMed/NCBI

Du K, Wei S, Wei Z, Frederick DT, Miao B, Moll T, Tian T, Sugarman E, Gabrilovich DI, Sullivan RJ, et al: Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nat Commun. 12:60232021. View Article : Google Scholar : PubMed/NCBI

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, et al: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 549:101–105. 2017. View Article : Google Scholar : PubMed/NCBI

Vranic S and Gatalica Z: PD-L1 testing by immunohistochemistry in immuno-oncology. Biomol Biomed. 23:15–25. 2023. View Article : Google Scholar :

Ye Z, Xiong Y, Peng W, Wei W, Huang L, Yue J, Zhang C, Lin G, Huang F, Zhang L, et al: Manipulation of PD-L1 endosomal trafficking promotes anticancer immunity. Adv Sci (Weinh). 10:e22064112023. View Article : Google Scholar :

Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, et al: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 553:91–95. 2018. View Article : Google Scholar :

Mei J, Xu J, Yang X, Gu D, Zhou W, Wang H and Liu C: A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: Evidence from immunohistochemical analysis. Mol Cancer. 20:112021. View Article : Google Scholar : PubMed/NCBI

Wang Q, Wang J, Yu D, Zhang Q, Hu H, Xu M, Zhang H, Tian S, Zheng G, Lu D, et al: Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell Rep Med. 5:1013572024. View Article : Google Scholar : PubMed/NCBI

Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, et al: Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 33:187–201.e10. 2018. View Article : Google Scholar : PubMed/NCBI

Shi YY, Fan G, Tan R, Li S, Sun HB, Li R, Yang M, Gao S, Liu M and Dai MY: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates. Cell Death Dis. 15:7012024. View Article : Google Scholar : PubMed/NCBI

Shi F, Li GJ, Liu Y, Zhou HM, Zhang Y, Wei SY, Zan BJ, Gao M, Chen FS, Li BX, et al: USP19 deficiency enhances T-cell-mediated antitumor immunity by promoting PD-L1 degradation in colorectal cancer. Pharmacol Res. 214:1076682025. View Article : Google Scholar : PubMed/NCBI

Dong T, Niu H, Chu Z, Zhou C, Gao Y, Jia M, Sun B, Zheng X, Zhang W, Zhang J, et al: Targeting VPS18 hampers retromer trafficking of PD-L1 and augments immunotherapy. Sci Adv. 10:eadp49172024. View Article : Google Scholar : PubMed/NCBI

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, et al: A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 3:1051–1058. 2017. View Article : Google Scholar : PubMed/NCBI

Wang SC, Shen YC, Pan MR, Ou-Yang F, Liao TY, Liu LC, Rau KM, Lu LS, Huang CC, Dai MS, et al: Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: A real-world study in breast cancer patients in Taiwan. Cancer Lett. 631:2179122025. View Article : Google Scholar : PubMed/NCBI

Shu Z, Dwivedi B, Switchenko JM, Yu DS and Deng X: PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer. Nat Commun. 15:68302024. View Article : Google Scholar : PubMed/NCBI

Xu J, Yang X, Mao Y, Mei J, Wang H, Ding J and Hua D: Removal of N-linked glycosylation enhances PD-L1 detection in colon cancer: Validation research based on immunohistochemistry analysis. Technol Cancer Res Treat. 20:153303382110194422021. View Article : Google Scholar : PubMed/NCBI

Ou-Yang F, Li CL, Chen CC, Shen YC, Moi SH, Luo CW, Xia WY, Wang YN, Lee HH, Wang LH, et al: De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients. Am J Cancer Res. 12:123–137. 2022.PubMed/NCBI

Wang H, Yao H, Li C, Shi H, Lan J, Li Z, Zhang Y, Liang L, Fang JY and Xu J: HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 15:42–50. 2019. View Article : Google Scholar

Zhou Z, Lu Y, Li P, Liu X, Cheng W, Chen HN, Dai L and Ren H: The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. PLoS Biol. 24:e30036032026. View Article : Google Scholar : PubMed/NCBI

Shi YY, Wang AJ, Liu XL, Dai MY and Cai HB: Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells. Front Immunol. 14:11932222023. View Article : Google Scholar : PubMed/NCBI

Wu Y, Zhang C, Liu X, He Z, Shan B, Zeng Q, Zhao Q, Zhu H, Liao H, Cen X, et al: ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nat Commun. 12:23462021. View Article : Google Scholar : PubMed/NCBI

Liu C, Yao Z, Wang J, Zhang W, Yang Y, Zhang Y, Qu X, Zhu Y, Zou J, Peng S, et al: Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway. Cell Death Differ. 27:1765–1781. 2020. View Article : Google Scholar

Wang Y, Sun Q, Mu N, Sun X, Wang Y, Fan S, Su L and Liu X: The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Commun Signal. 18:1122020. View Article : Google Scholar : PubMed/NCBI

Huang X, Zhang Q, Lou Y, Wang J, Zhao X, Wang L, Zhang X, Li S, Zhao Y, Chen Q, et al: USP22 deubiquitinates CD274 to suppress anticancer immunity. Cancer Immunol Res. 7:1580–1590. 2019. View Article : Google Scholar : PubMed/NCBI

Wang Z, Kang W, Li O, Qi F, Wang J, You Y, He P, Suo Z, Zheng Y and Liu HM: Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharm Sin B. 11:694–707. 2021. View Article : Google Scholar : PubMed/NCBI

Jingjing W, Wenzheng G, Donghua W, Guangyu H, Aiping Z and Wenjuan W: Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma. Cancer Med. 7:4004–4011. 2018. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Huang Y, Yu D, Xu M, Hu H, Zhang Q, Cai M, Geng X, Zhang H, Xia J, et al: Demethylzeylasteral induces PD-L1 ubiquitin-proteasome degradation and promotes antitumor immunity via targeting USP22. Acta Pharm Sin B. 14:4312–4328. 2024. View Article : Google Scholar : PubMed/NCBI

Kaufman B, Abu-Ahmad M, Radinsky O, Gharra E, Manko T, Bhattacharya B, Gologan D, Erlichman N, Meshel T, Nuta Y, et al: N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1. Mol Cancer. 24:1402025. View Article : Google Scholar : PubMed/NCBI

Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, Tixier L, Danel C, Damiola F, Damotte D, et al: Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 29:953–958. 2018. View Article : Google Scholar : PubMed/NCBI

Krigsfeld GS, Prince EA, Pratt J, Chizhevsky V, William Ragheb J, Novotny J Jr and Huron D: Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types. J Clin Pathol. 73:656–664. 2020. View Article : Google Scholar : PubMed/NCBI

Maule JG, Clinton LK, Graf RP, Xiao J, Oxnard GR, Ross JS and Huang RSP: Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. J Immunother Cancer. 10:e0055732022. View Article : Google Scholar : PubMed/NCBI

Paliogiannis P, Lobrano R, Bella MA, Fara A, Uras MG, Pinna MA, Tedde A, Madonia M, Zinellu A and Cossu A: PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study. Ann Diagn Pathol. 69:1522672024. View Article : Google Scholar : PubMed/NCBI

Saberzadeh-Ardestani B, Graham RP, McMahon S, Ahanonu E, Shi Q, Williams C, Hubbard A, Zhang W, Muranyi A, Yan D, et al: Immune marker spatial distribution and clinical outcome after PD-1 blockade in mismatch repair-deficient, advanced colorectal carcinomas. Clin Cancer Res. 29:4268–2477. 2023. View Article : Google Scholar : PubMed/NCBI

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, et al: Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 7:1420–1435. 2017. View Article : Google Scholar : PubMed/NCBI

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, et al: Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7:188–201. 2017. View Article : Google Scholar

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al: IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 127:2930–2940. 2017. View Article : Google Scholar : PubMed/NCBI

Kaul S, Cole NB, Bandola-Simon J, Lu Y, Tondini E, Walseng E and Roche PA: CD83 suppresses endogenous March-I-dependent MHC class II ubiquitination, endocytosis, and degradation. Proc Natl Acad Sci USA. 122:e25040771222025. View Article : Google Scholar : PubMed/NCBI

Kim HJ, Bandola-Simon J, Ishido S, Wong NW, Koparde VN, Cam M and Roche PA: Ubiquitination of MHC class II by March-I regulates dendritic cell fitness. J Immunol. 206:494–504. 2021. View Article : Google Scholar

Zhang Y, Chen Y, Liu Z and Lai R: ERK is a negative feedback regulator for IFN-γ/STAT1 signaling by promoting STAT1 ubiquitination. BMC Cancer. 18:6132018. View Article : Google Scholar

Huang HC, Huang YL, Chen YJ, Wu HY, Hsu CL, Kao HF, Liao BC, Hsieh MS, Lin NY, Liao YH, et al: The branched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC. Oncogenesis. 13:362024. View Article : Google Scholar : PubMed/NCBI

Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, et al: Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 8:11362017. View Article : Google Scholar : PubMed/NCBI

Liu H, Jain R, Guan J, Vuong V, Ishido S, La Gruta NL, Gray DH, Villadangos JA and Mintern JD: Ubiquitin ligase MARCH 8 cooperates with CD83 to control surface MHC II expression in thymic epithelium and CD4 T cell selection. J Exp Med. 213:1695–1703. 2016. View Article : Google Scholar : PubMed/NCBI

McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, et al: Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 171:1259–1271.e11. 2017. View Article : Google Scholar : PubMed/NCBI

Mittal SK, Cho KJ, Ishido S and Roche PA: Interleukin 10 (IL-10)-mediated immunosuppression: March-I induction regulates antigen presentation by macrophages but not dendritic cells. J Biol Chem. 290:27158–27167. 2015. View Article : Google Scholar : PubMed/NCBI

Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, et al: MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 574:696–701. 2019. View Article : Google Scholar : PubMed/NCBI

Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu DD, et al: LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nat Cancer. 3:355–370. 2022. View Article : Google Scholar : PubMed/NCBI

Tcyganov EN, Sanseviero E, Marvel D, Beer T, Tang HY, Hembach P, Speicher DW, Zhang Q, Donthireddy LR, Mostafa A, et al: Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. Cancer Cell. 40:1173–1189.e6. 2022. View Article : Google Scholar : PubMed/NCBI

Lei X, Lin H, Wang J, Ou Z, Ruan Y, Sadagopan A, Chen W, Xie S, Chen B, Li Q, et al: Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression. Nat Commun. 13:38822022. View Article : Google Scholar : PubMed/NCBI

Tong S, Cinelli MA, El-Sayed NS, Huang H, Patel A, Silverman RB and Yang S: Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS). Sci Rep. 12:17012022. View Article : Google Scholar : PubMed/NCBI

Marijt KA, Sluijter M, Blijleven L, Tolmeijer SH, Scheeren FA, van der Burg SH and van Hall T: Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling. J Immunother Cancer. 7:1522019. View Article : Google Scholar

Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, et al: Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 167:1540–1554.e12. 2016. View Article : Google Scholar : PubMed/NCBI

Chandrasekaran S, Sasaki M, Scharer CD, Kissick HT, Patterson DG, Magliocca KR, Seykora JT, Sapkota B, Gutman DA, Cooper LA, et al: Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression. Mol Cancer Res. 17:2395–2409. 2019. View Article : Google Scholar : PubMed/NCBI

Shuai K, Stark GR, Kerr IM and Darnell JE Jr: A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science. 261:1744–1746. 1993. View Article : Google Scholar : PubMed/NCBI

Lawrence DW and Kornbluth J: E3 ubiquitin ligase NKLAM ubiquitinates STAT1 and positively regulates STAT1-mediated transcriptional activity. Cell Signal. 28:1833–1841. 2016. View Article : Google Scholar : PubMed/NCBI

Zhu Z, Tang R, Huff S, Kummetha IR, Wang L, Li N and Rana TM: Small-molecule PTPN2 inhibitors sensitize resistant melanoma to Anti-PD-1 immunotherapy. Cancer Res Commun. 3:119–129. 2023. View Article : Google Scholar : PubMed/NCBI

Mizuno S, Mizuno Y, Abe K, Macy AM, Chong KK, Kobayashi Y, Hastings KT, Hoon DSB and Bustos MA: Interferon-gamma-inducible protein 30 prevents IFN-γ-receptor 1 degradation to maintain PD-L1 and MHC-II levels in metastatic melanoma. Cell Commun Signal. 24:1822026. View Article : Google Scholar

Kraemer AI, Chong C, Huber F, Pak H, Stevenson BJ, Müller M, Michaux J, Altimiras ER, Rusakiewicz S, Simó-Riudalbas L, et al: The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer. Nat Cancer. 4:608–628. 2023. View Article : Google Scholar : PubMed/NCBI

Hoenisch Gravel N, Nelde A, Bauer J, Mühlenbruch L, Schroeder SM, Neidert MC, Scheid J, Lemke S, Dubbelaar ML, Wacker M, et al: TOF_IMS mass spectrometry-based immunopeptidomics refines tumor antigen identification. Nat Commun. 14:74722023. View Article : Google Scholar

Salek M, Förster JD, Becker JP, Meyer M, Charoentong P, Lyu Y, Lindner K, Lotsch C, Volkmar M, Momburg F, et al: optiPRM: A targeted immunopeptidomics LC-MS workflow with ultra-high sensitivity for the detection of mutation-derived tumor neoepitopes from limited input material. Mol Cell Proteomics. 23:1008252024. View Article : Google Scholar :

Phulphagar KM, Ctortecka C, Jacome ASV, Klaeger S, Verzani EK, Hernandez GM, Udeshi ND, Clauser KR, Abelin JG and Carr SA: Sensitive, high-throughput HLA-I and HLA-II immunopeptidomics using parallel accumulation-serial fragmentation mass spectrometry. Mol Cell Proteomics. 22:1005632023. View Article : Google Scholar : PubMed/NCBI

Cui Y, Phuong K, Abdelfattah NS, Temple HM, Maiorino L, Kim BJ, Dye J, Yu KKH, Spranger S, Irvine DJ and White FM: Quantitative cell type-specific immunopeptidome analysis of macrophage and tumor coevolution reveals therapeutic MHC-I peptides in glioblastoma. Cancer Res. 85:4958–4976. 2025. View Article : Google Scholar : PubMed/NCBI

Mangalaparthi KK, Madugundu AK, Ryan ZC, Garapati K, Peterson JA, Dey G, Prakash A and Pandey A: Digging deeper into the immunopeptidome: Characterization of post-translationally modified peptides presented by MHC I. J Proteins Proteom. 12:151–160. 2021. View Article : Google Scholar : PubMed/NCBI

Faridi P, Woods K, Ostrouska S, Deceneux C, Aranha R, Duscharla D, Wong SQ, Chen W, Ramarathinam SH, Lim Kam Sian TCC, et al: Spliced Peptides and cytokine-driven changes in the immunopeptidome of melanoma. Cancer Immunol Res. 8:1322–1334. 2020. View Article : Google Scholar : PubMed/NCBI

Solleder M, Racle J, Guillaume P, Coukos G, Bassani-Sternberg M and Gfeller D: Deciphering the landscape of phosphorylated HLA-II ligands. iScience. 25:1042152022. View Article : Google Scholar : PubMed/NCBI

Molvi Z, Klatt MG, Dao T, Urraca J, Scheinberg DA and O'Reilly RJ: The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. J Immunother Cancer. 11:e0068892023. View Article : Google Scholar : PubMed/NCBI

Engelhard VH, Obeng RC, Cummings KL, Petroni GR, Ambakhutwala AL, Chianese-Bullock KA, Smith KT, Lulu A, Varhegyi N, Smolkin ME, et al: MHC-restricted phosphopeptide antigens: Preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. J Immunother Cancer. 8:e0002622020. View Article : Google Scholar : PubMed/NCBI

Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, et al: Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 7:134042016. View Article : Google Scholar : PubMed/NCBI

Fritsche J, Rakitsch B, Hoffgaard F, Römer M, Schuster H, Kowalewski DJ, Priemer M, Stos-Zweifel V, Hörzer H, Satelli A, et al: Translating immunopeptidomics to immunotherapy-decision-making for patient and personalized target selection. Proteomics. 18:e17002842018. View Article : Google Scholar :

Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Peralta R, Wang Y, Wang Y, DePeaux K, et al: Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 22:205–215. 2021. View Article : Google Scholar : PubMed/NCBI

Peralta RM, Xie B, Lontos K, Nieves-Rosado H, Spahr K, Joshi S, Ford BR, Quann K, Frisch AT, Dean V, et al: Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat Immunol. 25:2297–2307. 2024. View Article : Google Scholar : PubMed/NCBI

Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B, Smith M, Herrera PS, Chang HY, Satpathy AT, et al: Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 21:1022–1033. 2020. View Article : Google Scholar : PubMed/NCBI

Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, Casella V, Ngiow SF, Khan O, Huang YJ, et al: Developmental relationships of four exhausted CD8⁺ T cell subsets reveals underlying transcriptional and epigenetic landscape mechanisms. Immunity. 52:825–841.e8. 2020. View Article : Google Scholar

Shi X, Zhang D, Li F, Zhang Z, Wang S, Xuan Y, Ping Y and Zhang Y: Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity. J Hematol Oncol. 12:1272019. View Article : Google Scholar : PubMed/NCBI

Morrison E, Wegner T, Zucchetti AE, Álvaro-Benito M, Zheng A, Kliche S, Krause E, Brügger B, Hivroz C and Freund C: Dynamic palmitoylation events following T-cell receptor signaling. Commun Biol. 3:3682020. View Article : Google Scholar : PubMed/NCBI

Gallagher MP, Conley JM, Vangala P, Garber M, Reboldi A and Berg LJ: Hierarchy of signaling thresholds downstream of the T cell receptor and the Tec kinase ITK. Proc Natl Acad Sci USA. 118:e20258251182021. View Article : Google Scholar : PubMed/NCBI

Hu H, Wang H, Xiao Y, Jin J, Chang JH, Zou Q, Xie X, Cheng X and Sun SC: Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination. J Exp Med. 213:399–414. 2016. View Article : Google Scholar : PubMed/NCBI

Guo C, You Z, Shi H, Sun Y, Du X, Palacios G, Guy C, Yuan S, Chapman NM, Lim SA, et al: SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature. 620:200–208. 2023. View Article : Google Scholar : PubMed/NCBI

Verma S, Budhu S, Serganova I, Dong L, Mangarin LM, Khan JF, Bah MA, Assouvie A, Marouf Y, Schulze I, et al: Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models. J Clin Invest. 134:e1776062024. View Article : Google Scholar : PubMed/NCBI

Wang S, Huang T, Wu Q, Yuan H, Wu X, Yuan F, Duan T, Taori S, Zhao Y, Snyder NW, et al: Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. J Clin Invest. 134:e1768512024. View Article : Google Scholar : PubMed/NCBI

Sun K, Zhang X, Shi J, Huang J, Wang S, Li X, Lin H, Zhao D, Ye M, Zhang S, et al: Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. J Clin Invest. 135:e1870242025. View Article : Google Scholar : PubMed/NCBI

Nokin MJ, Durieux F, Bellier J, Peulen O, Uchida K, Spiegel DA, Cochrane JR, Hutton CA, Castronovo V and Bellahcène A: Hormetic potential of methylglyoxal, a side-product of glycolysis, in switching tumours from growth to death. Sci Rep. 7:117222017. View Article : Google Scholar : PubMed/NCBI

Kong LR, Gupta K, Wu AJ, Perera D, Ivanyi-Nagy R, Ahmed SM, Tan TZ, Tan SL, Fuddin A, Sundaramoorthy E, et al: A glycolytic metabolite bypasses 'two-hit' tumor suppression by BRCA2. Cell. 187:2269–2287.e16. 2024. View Article : Google Scholar

Di Sanzo S, Spengler K, Leheis A, Kirkpatrick JM, Rändler TL, Baldensperger T, Dau T, Henning C, Parca L, Marx C, et al: Mapping protein carboxymethylation sites provides insights into their role in proteostasis and cell proliferation. Nat Commun. 12:67432021. View Article : Google Scholar : PubMed/NCBI

Baumann T, Dunkel A, Schmid C, Schmitt S, Hiltensperger M, Lohr K, Laketa V, Donakonda S, Ahting U, Lorenz-Depiereux B, et al: Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal. Nat Immunol. 21:555–566. 2020. View Article : Google Scholar : PubMed/NCBI

Elia I, Rowe JH, Johnson S, Joshi S, Notarangelo G, Kurmi K, Weiss S, Freeman GJ, Sharpe AH and Haigis MC: Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8⁺ T cells. Cell Metabol. 34:1137–1150.e6. 2022. View Article : Google Scholar

Tsai YL, Arias-Badia M, Kadlecek TA, Lwin YM, Srinath A, Shah NH, Wang ZE, Barber D, Kuriyan J, Fong L and Weiss A: TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments. Immunity. 56:2682–2698.e9. 2023. View Article : Google Scholar

Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, et al: A transcriptionally and functionally distinct PD-1⁺ CD8⁺ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 24:994–1004. 2018. View Article : Google Scholar : PubMed/NCBI

Bannoud N, Dalotto-Moreno T, Kindgard L, García PA, Blidner AG, Mariño KV, Rabinovich GA and Croci DO: Hypoxia supports differentiation of terminally exhausted CD8 T cells. Front Immunol. 12:6609442021. View Article : Google Scholar : PubMed/NCBI

Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, et al: Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity. 45:389–401. 2016. View Article : Google Scholar : PubMed/NCBI

Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, et al: Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 545:452–456. 2017. View Article : Google Scholar : PubMed/NCBI

Thommen DS and Schumacher TN: T cell dysfunction in cancer. Cancer Cell. 33:547–562. 2018. View Article : Google Scholar : PubMed/NCBI

Trujillo JA, Sweis RF, Bao R and Luke JJ: T cell-inflamed versus non-T cell-inflamed tumors: A conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol Res. 6:990–1000. 2018. View Article : Google Scholar : PubMed/NCBI

Azevedo CM, Xie B, Gunn WG, Peralta RM, Dantas CS, Fernandes-Mendes H, Joshi S, Dean V, Almeida P, Wilfahrt D, et al: Reprogramming CD8+ T-cell branched N-glycosylation limits exhaustion, enhancing cytotoxicity and tumor killing. Cancer Immunol Res. 13:1655–1673. 2025. View Article : Google Scholar : PubMed/NCBI

Sun L, Li CW, Chung EM, Yang R, Kim YS, Park AH, Lai YJ, Yang Y, Wang YH, Liu J, et al: Targeting glycosylated PD-1 induces potent antitumor immunity. Cancer Res. 80:2298–2310. 2020. View Article : Google Scholar : PubMed/NCBI

Lu B, Sun YY, Chen BY, Yang B, He QJ, Li J and Cao J: zDHHC20-driven S-palmitoylation of CD80 is required for its costimulatory function. Acta Pharmacol Sin. 45:1214–1223. 2024. View Article : Google Scholar : PubMed/NCBI

Tewari R, Shayahati B, Fan Y and Akimzhanov AM: T cell receptor-dependent S-acylation of ZAP-70 controls activation of T cells. J Biol Chem. 296:1003112021. View Article : Google Scholar : PubMed/NCBI

Bieerkehazhi S, Fan Y, West SJ, Tewari R, Ko J, Mills T, Boehning D and Akimzhanov AM: Ca²⁺-dependent protein acyltransferase DHHC21 controls activation of CD4+ T cells. J Cell Sci. 135:jcs2581862022. View Article : Google Scholar

Voisinne G, Locard-Paulet M, Froment C, Maturin E, Menoita MG, Girard L, Mellado V, Burlet-Schiltz O, Malissen B, Gonzalez de Peredo A and Roncagalli R: Kinetic proofreading through the multi-step activation of the ZAP70 kinase underlies early T cell ligand discrimination. Nat Immunol. 23:1355–1364. 2022. View Article : Google Scholar : PubMed/NCBI

Wither MJ, White WL, Pendyala S, Leanza PJ, Fowler DM and Kueh HY: Antigen perception in T cells by long-term Erk and NFAT signaling dynamics. Proc Natl Acad Sci USA. 120:e23083661202023. View Article : Google Scholar : PubMed/NCBI

O'Donoghue GP, Bugaj LJ, Anderson W, Daniels KG, Rawlings DJ and Lim WA: T cells selectively filter oscillatory signals on the minutes timescale. Proc Natl Acad Sci USA. 118:e20192851182021. View Article : Google Scholar : PubMed/NCBI

Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL and Delgoffe GM: The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 45:701–703. 2016. View Article : Google Scholar : PubMed/NCBI

Jahan AS, Lestra M, Swee LK, Fan Y, Lamers MM, Tafesse FG, Theile CS, Spooner E, Bruzzone R, Ploegh HL and Sanyal S: Usp12 stabilizes the T-cell receptor complex at the cell surface during signaling. Proc Natl Acad Sci USA. 113:E705–E714. 2016. View Article : Google Scholar : PubMed/NCBI

Carrillo Roas S, Yagita Y, Murphy P, Kurzbauer R, Clausen T, Zavodszky E and Hegde RS: Convergence of orphan quality control pathways at a ubiquitin chain-elongating ligase. Mol Cell. 85:815–828.e10. 2025. View Article : Google Scholar : PubMed/NCBI

Liao X, Li W, Zhou H, Rajendran BK, Li A, Ren J, Luan Y, Calderwood DA, Turk B, Tang W, et al: The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8⁺ T cells. Nat Commun. 15:6032024. View Article : Google Scholar

Kumar J, Kumar R, Kumar Singh A, Tsakem EL, Kathania M, Riese MJ, Theiss AL, Davila ML and Venuprasad K: Deletion of Cbl-b inhibits CD8⁺ T-cell exhaustion and promotes CAR T-cell function. J Immunother Cancer. 9:e0016882021. View Article : Google Scholar

Wagle MV, Marchingo JM, Howitt J, Tan SS, Goodnow CC and Parish IA: The ubiquitin ligase adaptor NDFIP1 selectively enforces a CD8⁺ T cell tolerance checkpoint to high-dose antigen. Cell Rep. 24:577–584. 2018. View Article : Google Scholar : PubMed/NCBI

Yu YR, Imrichova H, Wang H, Chao T, Xiao Z, Gao M, Rincon-Restrepo M, Franco F, Genolet R, Cheng WC, et al: Disturbed mitochondrial dynamics in CD8⁺ TILs reinforce T cell exhaustion. Nat Immunol. 21:1540–1551. 2020. View Article : Google Scholar : PubMed/NCBI

Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, et al: Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 354:1160–1165. 2016. View Article : Google Scholar : PubMed/NCBI

Abdel-Hakeem MS, Manne S, Beltra JC, Stelekati E, Chen Z, Nzingha K, Ali MA, Johnson JL, Giles JR, Mathew D, et al: Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. Nat Immunol. 22:1008–1019. 2021. View Article : Google Scholar : PubMed/NCBI

Eggert J, Zinzow-Kramer WM, Hu Y, Kolawole EM, Tsai YL, Weiss A, Evavold BD, Salaita K, Scharer CD and Au-Yeung BB: Cbl-b mitigates the responsiveness of naive CD8⁺ T cells that experience extensive tonic T cell receptor signaling. Sci Signal. 17:eadh04392024. View Article : Google Scholar

Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, et al: TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. Nature. 571:211–218. 2019. View Article : Google Scholar : PubMed/NCBI

Leutert M, Entwisle SW and Villén J: Decoding post-translational modification crosstalk with proteomics. Mol Cell Proteomics. 20:1001292021. View Article : Google Scholar : PubMed/NCBI

Minguez P, Letunic I, Parca L, Garcia-Alonso L, Dopazo J, Huerta-Cepas J and Bork P: PTMcode v2: A resource for functional associations of post-translational modifications within and between proteins. Nucleic Acids Res. 43(Database Issue): D494–D502. 2015. View Article : Google Scholar :

Okada M, Chikuma S, Kondo T, Hibino S, Machiyama H, Yokosuka T, Nakano M and Yoshimura A: Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells. Cell Rep. 20:1017–1028. 2017. View Article : Google Scholar : PubMed/NCBI

Hundt M, Tabata H, Jeon MS, Hayashi K, Tanaka Y, Krishna R, De Giorgio L, Liu YC, Fukata M and Altman A: Impaired activation and localization of LAT in anergic T cells as a consequence of a selective palmitoylation defect. Immunity. 24:513–522. 2006. View Article : Google Scholar : PubMed/NCBI

Fukushi A, Kim HD, Chang YC and Kim CH: Revisited metabolic control and reprogramming cancers by means of the warburg effect in tumor cells. Int J Mol Sci. 23:100372022. View Article : Google Scholar : PubMed/NCBI

Wang RH, Chen PR, Chen YT, Chen YC, Chu YH, Chien CC, Chien PC, Lo SY, Wang ZL, Tsou MC, et al: Hydrogen sulfide coordinates glucose metabolism switch through destabilizing tetrameric pyruvate kinase M2. Nat Commun. 15:74632024. View Article : Google Scholar : PubMed/NCBI

Nie H, Ju H, Fan J, Shi X, Cheng Y, Cang X, Zheng Z, Duan X and Yi W: O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth. Nat Commun. 11:362020. View Article : Google Scholar : PubMed/NCBI

Duan Y, Li J, Wang F, Wei J, Yang Z, Sun M, Liu J, Wen M, Huang W, Chen Z, et al: Protein modifications throughout the lung cancer proteome unravel the cancer-specific regulation of glycolysis. Cell Rep. 37:1101372021. View Article : Google Scholar : PubMed/NCBI

Schachner LF, Soye BD, Ro S, Kenney GE, Ives AN, Su T, Goo YA, Jewett MC, Rosenzweig AC and Kelleher NL: Revving an engine of human metabolism: Activity enhancement of triosephosphate isomerase via hemi-phosphorylation. ACS Chem Biol. 17:2769–2780. 2022. View Article : Google Scholar : PubMed/NCBI

Zhang JJ, Fan TT, Mao YZ, Hou JL, Wang M, Zhang M, Lin Y, Zhang L, Yan GQ, An YP, et al: Nuclear dihydroxyacetone phosphate signals nutrient sufficiency and cell cycle phase to global histone acetylation. Nat Metab. 3:859–875. 2021. View Article : Google Scholar : PubMed/NCBI

Li Y, Shi X, Zhang F, Zhou X, Zhu X, Chen J, Fu K, Chen J, Yang J, Chen Z, et al: HDAC11-mediated deacetylation of triosephosphate isomerase 1 promotes idiopathic pulmonary fibrosis. Research (Wash D C). 8:09532025.PubMed/NCBI

Xiong J, He J, Zhu J, Pan J, Liao W, Ye H, Wang H, Song Y, Du Y, Cui B, et al: Lactylation-driven METTL3-mediated RNA m⁶A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 82:1660–1677.e10. 2022. View Article : Google Scholar

Tan Y, Tan W, Liang Y, Long Y, Chen S, Hu Q, Ou Y, Fu J, Chen H, Ren F, et al: Machine learning-enabled spatial multi-omics uncovers lactate-driven targets and tumor microenvironmental reprogramming in cancer. NPJ Digit Med. 9:1092025. View Article : Google Scholar : PubMed/NCBI

Zhang B, Xu A, Wang H, Yan W, Zhang Q and Wang S: MPC-mediated lactate production drives histone lactylation in dendritic cells to affect tumor progression and immunotherapy. Cell Mol Life Sci. 82:3712025. View Article : Google Scholar : PubMed/NCBI

Kourtis S, Gañez Zapater A, Elbæk CR, Schmidt A, Ghose R, Coll Manzano A, Espinar Calvo L, Guirola M, Pardo-Lorente N, Garcia-Cao M, et al: Native chromatome profiling reveals hundreds of metabolic enzymes in the nucleus across tissues. Nat Commun. 17:16552026. View Article : Google Scholar : PubMed/NCBI

Dai M, Yang B, Chen J, Liu F, Zhou Y, Zhou Y, Xu Q, Jiang S, Zhao S, Li X, et al: Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer. Cancer Lett. 513:36–49. 2021. View Article : Google Scholar : PubMed/NCBI

Sdelci S, Rendeiro AF, Rathert P, You W, Lin JMG, Ringler A, Hofstätter G, Moll HP, Gürtl B, Farlik M, et al: MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nat Genet. 51:990–998. 2019. View Article : Google Scholar : PubMed/NCBI

Liu S, Pan Y, Liu W, Bu X, Shao R, Wang Q, Wu J, Wu C, Hu W, Xu J, et al: Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma. J Immunother Cancer. 13:e0122302025. View Article : Google Scholar : PubMed/NCBI

Zong Z, Zhang L and Zhou F: Lactylation in cancer: Advances, challenges, and future perspectives. Cancer Res. 85:3192–3195. 2025. View Article : Google Scholar : PubMed/NCBI

Zhang D, Gao J, Zhu Z, Mao Q, Xu Z, Singh PK, Rimayi CC, Moreno-Yruela C, Xu S, Li G, et al: Lysine L-lactylation is the dominant lactylation isomer induced by glycolysis. Nat Chem Biol. 21:91–99. 2025. View Article : Google Scholar

Jarmasz JS, Stirton H, Davie JR and Del Bigio MR: DNA methylation and histone post-translational modification stability in post-mortem brain tissue. Clin Epigenetics. 11:52019. View Article : Google Scholar : PubMed/NCBI

Liu J, Zhao L, Yan M, Jin S, Shang L, Wang J, Wang Q, Zhao S, Shen Z, Liu T, et al: H4K79 and H4K91 histone lactylation, newly identified lactylation sites enriched in breast cancer. J Exp Clin Cancer Res. 44:2522025. View Article : Google Scholar : PubMed/NCBI

Bauden M, Kristl T, Andersson R, Marko-Varga G and Ansari D: Characterization of histone-related chemical modifications in formalin-fixed paraffin-embedded and fresh-frozen human pancreatic cancer xenografts using LC-MS/MS. Lab Invest. 97:279–288. 2017. View Article : Google Scholar

Zhao L, Xing P, Polavarapu VK, Zhao M, Valero-Martínez B, Dang Y, Maturi N, Mathot L, Neves I, Yildirim I, et al: FACT-seq: Profiling histone modifications in formalin-fixed paraffin-embedded samples with low cell numbers. Nucleic Acids Res. 49:e1252021. View Article : Google Scholar : PubMed/NCBI

Pitter MR, Kryczek I, Zhang H, Nagarsheth N, Xia H, Wu Z, Tian Y, Okla K, Liao P, Wang W, et al: PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages. Cell Rep. 43:1139422024. View Article : Google Scholar : PubMed/NCBI

Zuo Y, Feng Q, Jin L, Huang F, Miao Y, Liu J, Xu Y, Chen X, Zhang H, Guo T, et al: Regulation of the linear ubiquitination of STAT1 controls antiviral interferon signaling. Nat Commun. 11:11462020. View Article : Google Scholar : PubMed/NCBI

Ugolini A, De Leo A, Yu X, Scirocchi F, Liu X, Peixoto B, Scocozza D, Pace A, Perego M, Gardini A, et al: Functional reprogramming of neutrophils within the brain tumor microenvironment by hypoxia-driven histone lactylation. Cancer Discov. 15:1270–1296. 2025. View Article : Google Scholar : PubMed/NCBI

Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, et al: Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 23:312–328. 2006. View Article : Google Scholar : PubMed/NCBI

Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, et al: Validation of biomarkers to predict response to immunotherapy in cancer: Volume I-pre-analytical and analytical validation. J Immunother Cancer. 4:762016. View Article : Google Scholar

Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ, et al: Validation of biomarkers to predict response to immunotherapy in cancer: Volume II-clinical validation and regulatory considerations. J Immunother Cancer. 4:772016. View Article : Google Scholar

Dressler FF, Schoenfeld J, Revyakina O, Vogele D, Kiefer S, Kirfel J, Gemoll T and Perner S: Systematic evaluation and optimization of protein extraction parameters in diagnostic FFPE specimens. Clin Proteomics. 19:102022. View Article : Google Scholar : PubMed/NCBI

Friedrich C, Schallenberg S, Kirchner M, Ziehm M, Niquet S, Haji M, Beier C, Neudecker J, Klauschen F and Mertins P: Comprehensive micro-scaled proteome and phosphoproteome characterization of archived retrospective cancer repositories. Nat Commun. 12:35762021. View Article : Google Scholar : PubMed/NCBI

Vassilakopoulou M, Parisi F, Siddiqui S, England AM, Zarella ER, Anagnostou V, Kluger Y, Hicks DG, Rimm DL and Neumeister VM: Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. Lab Invest. 95:334–341. 2015. View Article : Google Scholar

Haragan A, Liebler DC, Das DM, Soper MD, Morrison RD, Slebos RJC, Ackermann BL, Fill JA, Schade AE, Gosney JR and Gruver AM: Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry. Lab Invest. 100:874–886. 2020. View Article : Google Scholar : PubMed/NCBI

Wang W, He Y, Yuan X, Weng L, Bai J, Liu X, Han L, Xu J, Wang S, Lu S, et al: Protocol for Chinese lung cancer evolution and microenvironment tracking under therapy study. J Transl Int Med. 13:599–609. 2025. View Article : Google Scholar : PubMed/NCBI

Wacker M, Bauer J, Wessling L, Dubbelaar M, Nelde A, Rammensee HG and Walz JS: Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics. Front Immunol. 14:12197202023. View Article : Google Scholar : PubMed/NCBI

Shahbazy M, Ramarathinam SH, Illing PT, Jappe EC, Faridi P, Croft NP and Purcell AW: Benchmarking bioinformatics pipelines in data-independent acquisition mass spectrometry for immunopeptidomics. Mol Cell Proteomics. 22:1005152023. View Article : Google Scholar : PubMed/NCBI

Ran Z, Mu M, Lin S, Wang T, Zeng J, Kuang L, Chen K, Suo S, Yuan K and Xu H: Deciphering the MHC immunopeptidome of human cancers with ligand.MHC atlas. Brief Bioinform. 26:bbaf3142025. View Article : Google Scholar : PubMed/NCBI

Lim Kam Sian TCC, Goncalves G, Steele JR, Shamekhi T, Bramberger L, Jin D, Shahbazy M, Purcell AW, Ramarathinam S, Stoychev S and Faridi P: SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics. Front Immunol. 14:11075762023. View Article : Google Scholar : PubMed/NCBI

Wang YN, Lee HH, Wei Y, Chu YY, Xia W, Wang M, Yu D and Hung MC: An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. STAR Protoc. 3:1011982022. View Article : Google Scholar : PubMed/NCBI

Lawson NL, Scorer PW, Williams GH, Vandenberghe ME, Ratcliffe MJ and Barker C: Impact of decalcification, cold ischemia, and deglycosylation on performance of programmed cell death ligand-1 antibodies with different binding epitopes: Comparison of 7 clones. Mod Pathol. 36:1002202023. View Article : Google Scholar : PubMed/NCBI

Torlakovic E, Albadine R, Bigras G, Boag A, Bojarski A, Cabanero M, Camilleri-Broët S, Cheung C, Couture C, Craddock KJ, et al: Canadian multicenter project on standardization of programmed death-ligand 1 immunohistochemistry 22C3 laboratory-developed tests for pembrolizumab therapy in NSCLC. J Thorac Oncol. 15:1328–1337. 2020. View Article : Google Scholar : PubMed/NCBI

Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, Chowdhury A, Li YY, Wang X, Spurr L, et al: Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer. J Clin Oncol. 42:1311–1321. 2024. View Article : Google Scholar : PubMed/NCBI

Ma L, Heinrich S, Wang L, Keggenhoff FL, Khatib S, Forgues M, Kelly M, Hewitt SM, Saif A, Hernandez JM, et al: Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun. 13:75332022. View Article : Google Scholar : PubMed/NCBI

Kamatani T, Umeda K, Iwasawa T, Miya F, Matsumoto K, Mikami S, Hara K, Shimoda M, Suzuki Y, Nishino J, et al: Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma. Nat Commun. 16:79952025. View Article : Google Scholar : PubMed/NCBI

Quek C, Pratapa A, Bai X, Al-Eryani G, Pires da Silva I, Mayer A, Bartonicek N, Harvey K, Maher NG, Conway JW, et al: Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy. Cell Rep. 43:1143922024. View Article : Google Scholar : PubMed/NCBI

Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, Nowosad A, Roda N, Makhzami S, Bervoets G, et al: A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell. 187:166–183.e25. 2024. View Article : Google Scholar : PubMed/NCBI

Zhai W, Lin Y, Zhou Y, Wang Q, Zhao Z, Feng S, Rao B, Sun W, Wang Y, Zhou Z, et al: A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer. J Transl Int Med. 13:614–617. 2025. View Article : Google Scholar : PubMed/NCBI

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:1031–1037. 2001. View Article : Google Scholar : PubMed/NCBI

Takeda K, Umezawa R, Yamamoto T, Takahashi N, Suzuki Y, Kishida K, Omata S and Jingu K: Lymphocytopenia following adjuvant radiotherapy for breast cancer. Precis Radiat Oncol. 8:22–29. 2024. View Article : Google Scholar : PubMed/NCBI

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, et al: Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 132:393–404. 2018. View Article : Google Scholar : PubMed/NCBI

Baretti M, Danilova L, Durham JN, Betts CB, Cope L, Sidiropoulos DN, Tandurella JA, Charmsaz S, Gross N, Hernandez A, et al: Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: A phase 2 clinical trial. Nat Commun. 15:98012014. View Article : Google Scholar

Han J, Hua Y, Wu X, Tang X and Liu C: Chemoradio-immunotherapy versus chemoimmunotherapy or chemoradiotherapy in extensive-stage small-cell lung cancer: A retrospective analysis of survival outcomes. Precis Radiat Oncol. 9:295–303. 2025. View Article : Google Scholar :

Zheng H, Cui K, Mao J, Wan Y and Zheng J: Chimeric degraders in neurodegenerative diseases: Challenges and future directions. J Transl Int Med. 13:508–511. 2025. View Article : Google Scholar : PubMed/NCBI

Mahadevan D, Barve M, Mahalingam D, Parekh J, Kurman M, Strauss J, Tremaine L, Hromas R, Sills J, McCulloch J, et al: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies. J Hematol Oncol. 18:982025. View Article : Google Scholar : PubMed/NCBI

Flores-López LA, De la Mora-De la Mora I, Malagón-Reyes CM, García-Torres I, Martínez-Pérez Y, López-Herrera G, Hernández-Alcántara G, León-Avila G, López-Velázquez G, Olaya-Vargas A, et al: Selective inhibition of deamidated triosephosphate isomerase by disulfiram, curcumin, and sodium dichloroacetate: synergistic therapeutic strategies for T-cell acute lymphoblastic leukemia in jurkat cells. Biomolecules. 14:12952024. View Article : Google Scholar : PubMed/NCBI

Enríquez-Flores S, Flores-López LA, De la Mora-De la Mora I, García-Torres I, Gracia-Mora I, Gutiérrez-Castrellón P, Fernández-Lainez C, Martínez-Pérez Y, Olaya-Vargas A, de Vos P and López-Velázquez G: Naturally occurring deamidated triosephosphate isomerase is a promising target for cell-selective therapy in cancer. Sci Rep. 12:40282022. View Article : Google Scholar : PubMed/NCBI

Hu Z, Chen PH, Li W, Krone M, Zheng S, Saarbach J, Velasco IU, Hines J, Liu Y and Crews CM: EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling. Sci Adv. 10:eadj72512024. View Article : Google Scholar : PubMed/NCBI

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, et al: The target landscape of clinical kinase drugs. Science. 358:eaan43682017. View Article : Google Scholar : PubMed/NCBI

Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, et al: Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19:87–100. 2018. View Article : Google Scholar

Alabi S, Jaime-Figueroa S, Yao Z, Gao Y, Hines J, Samarasinghe KTG, Vogt L, Rosen N and Crews CM: Mutant-selective degradation by BRAF-targeting PROTACs. Nat Commun. 12:9202021. View Article : Google Scholar : PubMed/NCBI

Maneiro MA, Forte N, Shchepinova MM, Kounde CS, Chudasama V, Baker JR and Tate EW: Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4. ACS Chem Biol. 15:1306–1312. 2020. View Article : Google Scholar : PubMed/NCBI

Huber AD, Lin W, Jung YH, Poudel S, Yang G, Wu J, Carrigan AG, Pagala V, Wang W, Fu Y, et al: PROTAC repurposing uncovers a noncanonical binding surface that mediates chemical degradation of nuclear receptors. Nat Commun. 16:98052025. View Article : Google Scholar : PubMed/NCBI

Steger M, Nishiguchi G, Wu Q, Schwalb B, Shashikadze B, McGowan K, Actis M, Aggarwal A, Shi Z, Price J, et al: Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics. Nat Commun. 16:77732025. View Article : Google Scholar : PubMed/NCBI

Ives CM, Singh O, D'Andrea S, Fogarty CA, Harbison AM, Satheesan A, Tropea B and Fadda E: Restoring protein glycosylation with GlycoShape. Nat Methods. 21:2117–2127. 2024. View Article : Google Scholar : PubMed/NCBI

Tsai YX, Chang NE, Reuter K, Chang HT, Yang TJ, von Bülow S, Sehrawat V, Zerrouki N, Tuffery M, Gecht M, et al: Rapid simulation of glycoprotein structures by grafting and steric exclusion of glycan conformer libraries. Cell. 187:1296–1311.e26. 2024. View Article : Google Scholar : PubMed/NCBI

Vergoten G and Bailly C: N-glycosylation reinforces interaction of immune checkpoint TIM-3 with a small molecule ligand. Comput Biol Chem. 104:1078522023. View Article : Google Scholar : PubMed/NCBI

Zhang S, Wang HY, Tao X, Chen Z, Levental I and Lin X: Palmitoylation of PD-L1 regulates its membrane orientation and immune evasion. Langmuir. 41:5170–5178. 2025. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Ren C, Xiao R, Ma S, Liu H, Dou Y, Fan Y, Wang S, Zhan P, Gao C, et al: Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. Sci Immunol. 9:eadp73022024. View Article : Google Scholar : PubMed/NCBI

Kalinichenko A, Huemer J, Humer T, Haimel M, Svaton M, Socquet-Juglard N, Casoni GP, Prakash C, von der Linde M, Pazmandi J, et al: Protein palmitoylation and sphingolipid metabolism control regulated exocytosis in cytotoxic lymphocytes. Sci Immunol. 10:eado38252025. View Article : Google Scholar : PubMed/NCBI